Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.
Financial
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced a $50M Series B funding round led by Johnson & Johnson Innovation – JJDC, Inc. joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, […]
Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress
SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.
Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O’Neil as Chief Financial Officer and Erin Lavelle as Director
– Company continuing to advance clinical development of HU6, a novel oral, once-daily Controlled Metabolic Accelerator, in Phase 2 trials to treat obesity-related heart failure and metabolic dysfunction-associated steatohepatitis (MASH) – CHARLOTTESVILLE, Va. and SAN FRANCISCO, Sept. 11,…
HeartBeam Names Timothy Cruickshank as Chief Financial Officer
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Timothy Cruickshank as Chief Financial Officer (CFO), effective immediately. Mr. Cruickshank brings more than 15 years of public company experience with […]
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow’s initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate. “The improvement in […]
VasQ™ Extravascular Support Granted Transitional Pass-Through (TPT) Payment
Laminate Medical Technologies Thanks Kidney Patients for Advocacy NEW YORK, Sept. 10, 2024 /PRNewswire/ — Laminate Medical Technologies today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted their VasQ™ extravascular support device a Transitional…
Venova Medical Announces $30 Million Series B Financing and Appointment of New Board Member
Funding Will Support Clinical Studies of the VelocityTM pAVF System in Patients with Chronic Kidney and End-Stage Renal Disease (Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced the […]
Scientia Vascular Announces $14 Million Growth Financing Led by Piper Sandler Merchant Banking
WEST VALLEY CITY, Utah, Sept. 9, 2024 /PRNewswire/ — Scientia Vascular, a leader in neurovascular innovation, is pleased to announce the closing of a $14 million growth financing led by Piper Sandler Merchant Banking. The financing will enable Scientia to continue commercializing the…
CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook
Half-year sales of €3.3 million, exceeding 2023 full-year sales 20 implants of the Aeson® artificial heart performed in the first half of 2024 17% cash-burn1 reduction compared to the first half of 2023 2024 anticipated annual sales of €8 to €12 million Other 2024 operational objectives on track Active exploration of […]



